Searched for
BIOPHARMA
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Govt outlines next phase of pharma growthThe government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...
- Piyush Goyal meets Ernst & Young CEO, discusses India's role in global supply chainsUnion Minister Piyush Goyal said he held a meeting with Janet Truncale, Global Chair and CEO of EY, to discuss India's growing role in glob...
- GSK in talks to buy cancer biotech Nuvalent for more than $9 billionBritish drug giant GSK is reportedly in talks to acquire cancer drugmaker Nuvalent. The deal could be worth over nine billion dollars. Disc...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Japanese biotech developing tooth-regrowing drug raises $5.3 million to advance human trialsToregem BioPharma has secured $5.3 million to advance its experimental tooth-regeneration drug, TRG035, into Phase II clinical trials. The ...
- India steers boat through a risky channel between war clouds and El NinoIndia faces a challenging global economic outlook for 2026-27. Geopolitical tensions and volatile oil prices are key concerns. However, Ind...
- J&K attracts record ₹5,824 crore investment in 2025-26, 13x jumpJammu and Kashmir has achieved a record investment of over ₹5,800 crore in 2025-26. This marks a significant jump, thirteen times higher th...
- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Two Trades for Today: A biopharma firm for a 7.65% rise, a mid-cap healthcare stock for an upmove of about 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- Biocon reports 63% YoY fall in Q4 profit, final dividend of Rs. 0.50 recommendedBiocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges im...
- Biocon Q4 Results: Net profit down 57% at Rs 198.6 croreBiocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolida...
- Guardant Health to launch blood-based cancer test in India with Zydus LifesciencesGuardant Health is set to introduce a groundbreaking blood test in India for early cancer detection. This multi-cancer test, co-marketed by...
- Bombay HC backs GSK in Paxil trademark row against Shreya Life SciencesThe Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medici...
- Moderna stocks: MRNA shares jump in US Stock market today after pharma giant surpasses Wall Street estimatesModerna had earlier posted a loss of $2.52 per share a year earlier, while analysts expected a loss of $3.96 per share.
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Budget 2026: Sitharaman proposes Rs 10,000-crore Biopharma Shakti scheme to boost biopharma manufacturingThe proposed fund aims to position India as a global biopharma manufacturing hub
- Dr. Reddy's inks pact with Singapore firm Prestige BioPharma to commercialise Trastuzumab biosimilar in select countriesHyderabad, Dec 9- Prestige BioPharma Ltd, a Singapore-based firm and Dr. Reddy's Laboratories Ltd., on Thursday announced that the two comp...
- Pharma sector needs global collaboration: Industry leaders, government officialsAhead of the 14th edition of the annual BioPharma and Healthcare Summit, that bring stakeholders from India and the United States on one pl...
- 'Indian bio-pharma R&D spending could grow to $25 bn by 2025'India's bio-pharma sector may see a surge in R&D spending to about $25 billion in the next 15 years, according to a Boston Consulting Group...
Load More
